Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000349992

Medchemexpress LLC Revumenib | 2169919-21-3 | 99.99% | 630.82 | 200 MG
SDP

Catalog No. 5000349992
Encompass_Preferred

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell-based IC50 of 10-20 nM. It is intended for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). For research use only; not for sale to patients.

  • Potent and specific Menin-MLL inhibitor.
  • Applicable for research in MLL-rearranged acute leukemias (ALL and AML).
  • Shows in vivo plasma IC50 of 53 nM.
  • Provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts in vivo.

Catalog No. 50-003-49992 Supplier Medchemexpress LLC Supplier No. HY136175200MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell-based IC50 of 10-20 nM. It is intended for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). For research use only; not for sale to patients.

  • Potent and specific Menin-MLL inhibitor.
  • Applicable for research in MLL-rearranged acute leukemias (ALL and AML).
  • Shows in vivo plasma IC50 of 53 nM.
  • Provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts in vivo.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.